About Cenya ImagingCenya is developing imaging agents - BEACONS - to quantify cell therapies over extended periods of time. read more
About Cenya Imaging
Cenya is developing imaging agents - BEACONS - to quantify cell therapies over extended periods of time. Quantification using medical imaging has traditionally required the use of radiopharmaceuticals. For safety reasons, these have short half-lives and stringent dosing limits thus only enabling quantification over short periods. Cenya BEACONS make use of stable, non-radioactive perfluorocarbon tracers which can quantify cells over far longer periods using non-proton MRI. Furthermore, BEACONS may be adapted to entrap radiopharmaceutical tracers, if users wish to use PET or SPECT in the short term, and MRI in the longer term.
Medical imaging is the only suitable non-invasive approach to tracking cells in patients, but individual imaging modalities (eg MRI, PET, Ultrasound) have trade-offs that prevent any one of them from yielding all the data needed by cell therapy developers.
Cenya’s BEACON technology solves this due to its inherent flexibility to incorporate a range of imaging agents suited to the medical imaging modality(ies) that will yield the data of most use to a specific cell therapy developer.
Cenya Imaging details
- CEO: James Simon
- Affliated department: Tumor Immunology
- Researcher: Mangala Srinivas
- Year of incorporation: 2018